Mantoux test good predictor of HIV-positive women's response to HPV

Adam Legge
Published: 14 September 2007

Skin prick testing may be better than CD4 counts as a way of measuring the ability of a HIV-positive woman’s immune system to tackle human papillomavirus (HPV) infection, according to a study published in the September edition of AIDS.

HPV infection is common in HIV-positive women, and infection with HIV increases the risk of a woman developing cancerous or pre-cancerous cervical cell changes.

Cutaneous anergy testing – or skin prick testing - evaluates the ability of the body to mount an specific type of immune response and reflects the number and the capacity of certain immune cells throughout the body, not just in the skin. The word anergy means a lack of reaction by the body's defence mechanisms when exposed to foreign substances (antigens).

The most common test involves the Mantoux technique, where small amounts of antigens are injected just underneath the skin. The response is measured by how much the skin comes up in bumps - a hypersensitivity reaction as a result of the immune system attacking the antigen. Mantoux testing used to be used routinely to screen children for tuberculosis immunity by injecting a tiny amount of TB antigen and seeing if they responded.

Researchers in this new study used the Mantoux technique to measuring delayed-type hypersensitivity (DTH) immune responses in 1,029 HIV-negative and 272 HIV-positive women.

They injected three antigens under the skin – a yeast called Candida albicans, tetanus toxin and mumps – and measured the response. The women were also evaluated for the presence of HPV and cervical neoplasia and also had their CD4 counts and HIV loads measured.

Those women who had anergy - no DTH reaction to the skin prick test – were 70% more likely to have cervical neoplasia (odds ratio 1.70, 95% CI 1.16 to 2.48) and 24% more likely to be infected with a strain of HPV known to increase the risk of developing cancer (odds ratio 1.24, 95% CI 0.99 to 1.56). These figures were irrespective of CD4 count or presence of HIV.

The authors say these results suggest that anergy status provides information regarding immune control of HPV and cervical neoplasia not accounted for by CD4 and HIV levels in circulation.

Cutaneous anergy testing has the potential to be used in identifying those women at increased risk of HPV infection and cervical neoplasia and therefore cancer. But anergy testing for HPV would have to be greatly improved, possibly by evaluating the use of the virus itself as the stimulating antigen in the Mantoux test, they add.

They conclude that further research is needed to understand the functional deficiencies in DTH-related immune cells that correlate with HPV infection.


Harris TG et al. Association of cutaneous anergy with human papillomavirus and cervical neoplasia on HIV-seropositive and seronegative women. AIDS 21: 1933-1941, 2007.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.